Spacer-Containing Nucleic Acid Constructs for Cleaner Viral Packaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing parvoviral gene therapy vectors face challenges with contaminating nucleic acids and self-inactivating sequences, leading to reduced efficacy and vector toxicity, which hinder efficient packaging of viral genomes into capsid proteins.
Innovation Solution
Nucleic acid molecules with spacer sequences and inverted terminal repeats are designed to be efficiently packaged into viral particles, minimizing contaminating nucleic acids and optimizing packaging efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional parvoviral gene therapy vectors are used, then gene expression can be achieved, but contaminating nucleic acids are present in vector stocks causing toxicity and reduced efficacy
Solution Approach 1:
The patent extracts and removes contaminating nucleic acids from the vector stock through rigorous purification methods, isolating only the desired viral particles free from prokaryotic and baculoviral contaminants, antibiotic resistance genes, and high CpG content nucleic acids
Solution Approach 2:
The patent introduces intermediary purification steps and filtration methods between the vector production and administration stages, using specialized media and protocols to eliminate contaminants while preserving the therapeutic viral particles
2Reliability
If viral genomes with self-inactivating sequences are used, then safety is improved, but packaging efficiency into capsid proteins is reduced
Solution Approach 1:
The patent modifies parameters of the viral genome structure, including the arrangement and sequence of self-inactivating sequences, to optimize both safety functions and packaging efficiency, finding the right balance between these competing requirements
Solution Approach 2:
The patent introduces dynamic elements to the viral genome packaging process, using conditional packaging mechanisms that allow efficient capsid assembly while maintaining self-inactivating safety features, perhaps through temperature-dependent or pH-dependent packaging conditions
3Productivity
If higher doses of vector are administered, then therapeutic efficacy is improved, but vector toxicity increases due to contaminants
Solution Approach 1:
The patent converts the potential harm of high-dose administration into a benefit by implementing advanced purification techniques that allow safe high-dose therapy, transforming the toxicity problem into an opportunity for more effective treatment through rigorous contaminant removal
Data Source
AI summary
The present invention relates nucleic acid molecules and concatemers containing spacer sequences useful for the efficient packaging of viral particles so as to minimize the incorporation of contaminant nucleic acids into these vectors, as well as methods of producing such viral particles.